Oxford Biomedica (LON:OXB) Sets New 1-Year Low – What’s Next?

Oxford Biomedica plc (LON:OXB) hit a new 52-week low during mid-day trading on Thursday. The company traded as low as GBX 367.50 and last traded at GBX 569.37, with a volume of 253,422 shares. The stock had previously closed at GBX 552.

Analysts Set New Price Targets

Several research analysts have recently issued reports on OXB shares. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a GBX 595 price objective on shares of Oxford Biomedica in a research report on Wednesday, September 2nd. Royal Bank Of Canada reissued an “outperform” rating and set a GBX 900 target price on shares of Oxford Biomedica in a research report on Tuesday, September 1st. Finally, Jefferies Financial Group restated a “buy” rating and set a GBX 827 target price on shares of Oxford Biomedica in a research note on Monday, October 26th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of GBX 818.

Oxford Biomedica Stock Performance

The stock has a market cap of £688.64 million, a PE ratio of -17.80 and a beta of 1.11. The firm’s 50-day moving average is GBX 500.71 and its 200 day moving average is GBX 603.54. The company has a debt-to-equity ratio of 273.08, a quick ratio of 1.67 and a current ratio of 2.21.

Oxford Biomedica (LON:OXB) last issued its quarterly earnings data on Wednesday, September 23rd. The biopharmaceutical company reported GBX (30.39) earnings per share (EPS) for the quarter. Oxford Biomedica had a negative return on equity of 54.51% and a negative net margin of 23.23%. As a group, research analysts anticipate that Oxford Biomedica plc will post -31.08 EPS for the current year.

Insider Activity at Oxford Biomedica

In other Oxford Biomedica news, insider Roch Doliveux bought 20,250 shares of the firm’s stock in a transaction dated Wednesday, September 23rd. The stock was acquired at an average price of GBX 505 per share, for a total transaction of £102,262.50. Insiders own 25.83% of the company’s stock.

About Oxford Biomedica

Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world.

One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors.